Ventiv Health has announced a multi-year, integrated sales and marketing agreement with Dexcel Pharma. Ventiv Health will provide Dexcel with a nationwide sales force, including recruitment, training and operational support for their dental products. In addition, all product fulfillments will be handled by Promotech, a subsidiary of Ventiv Health.
Dexcel Pharma researches, develops and manufactures and markets prescription and non-prescription pharmaceuticals, as well as unique technologies for controlled drug delivery. The Company is strategically focused and targeted to the greatest market potential, offering proprietary technologies and formulations that improve outcomes in a range of therapeutic specialties.
The Dexcel Pharma Group is headquartered in Israel. It operates wholly owned subsidiaries in the US, Germany and the UK. Its 155,000 square feet production facility in central Israel and additional manufacturing plant in Jerusalem operate in compliance with Current Good Manufacturing Practice and are approved by the FDA, MCA other EU authorities and multinationals. — (menareport.com)
© 2003 Mena Report (www.menareport.com)
